Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4729 and HRS9531 in Adult Participants With MASH
NCT07660848Phase 2Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4729, HRS9531 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2026; status: recruiting.
02
Drugs
HRS-4729HRS9531
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07660848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660848.